Viva Biotech partners with NVIDIA to jointly drive a new AI-powered 'dry-wet closed-loop' drug discovery model

On March 16, 2026, at 1:30 PM Pacific Time, Viva Biotech (01873.HK) collaborated with NVIDIA to optimize the Proteina Complexa model and advance the design of mini-binders targeting ActRIIA. This target plays a key role in muscle atrophy and lean body mass imbalance, with the collaboration aiming to accelerate the discovery of novel therapeutic drugs via AI-driven design based on NVIDIA's technology.

This partnership highlights the advantage of Viva Biotech’s 'dry-wet experimental closed-loop' R&D process — combining ab initio computational design with high-throughput protein production and biophysical evaluation for designing ActRIIA binders. This integrated approach demonstrates how drug discovery can be accelerated through computer simulation predictions combined with wet-lab experimental validation, showcasing the effective synergy between NVIDIA's BioNeMo platform and Viva Biotech's AI-driven one-stop drug discovery platform in optimizing candidate drugs.

As an important part of this project, Viva Biotech used its AI technology for sequence screening and provided valuable feedback to optimize the original Proteina Complexa model. After iterative optimization, the design efficiency and targeting specificity of the mini-binders were significantly improved. Guided by AI-driven insights, we successfully explored unprecedented chemical space, greatly enhancing design specificity, and achieved significant reductions in both cost and time compared to traditional candidate drug selection processes. For more details, please refer to:https://research.nvidia.com/labs/genair/proteina-complexa/。

As a globally leading Contract Research Organization (CRO) specializing in AI-driven drug discovery (AIDD) and structure-based drug discovery (SBDD), Viva Biotech accelerates the discovery of small molecules, antibodies, peptides, fusion proteins, PROTAC/molecular glues, and RNA-targeting compounds by integrating computational modeling, generative AI, and robust wet-lab capabilities. Looking ahead, Viva Biotech will further strengthen AI algorithm development and apply its AI platform extensively across drug discovery and development to continuously optimize workflows, providing high-quality and high-value solutions to partners, and leading the new era of AI-driven drug discovery.

$VIVA BIOTECH (01873.HK)$

83K Views